Acta Med. 2020, 63: 31-42

https://doi.org/10.14712/18059694.2020.13

Association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke: a Huge Meta-Analysis based on 44 Studies

Mohammadali Jafaria, Mohammad Hossein Jarahzadehb, Seyed Alireza Dastgheibc, Neda Seifi-Shalamzarid, Ali Raee-Ezzabadia, Jalal Sadeghizadeh-Yazdie, Elahe Akbarianf, Hossein Neamatzadehg,h

aDepartment of Emergency Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
bDepartment of Anesthesiology and Critical Care, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
cDepartment of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
dDepartment of Emergency Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
eDepartment of Food Science and Technology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
fChildren Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
gDepartment of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
hMother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Received November 12, 2019
Accepted January 30, 2020

References

1. Wu J, Zhang X, Wang J, et al. Gene polymorphisms and circulating levels of the TNF-alpha are associated with ischemic stroke: A meta-analysis based on 19,873 individuals. International Immunopharmacology 2019; 75: 105827. <https://doi.org/10.1016/j.intimp.2019.105827>
2. Wang L, Ge H, Peng L, Wang B. A meta‐analysis of the relationship between VEGFR2 polymorphisms and atherosclerotic cardiovascular diseases. Clinical Cardiology 2019; 42(10): 860–5. <https://doi.org/10.1002/clc.23233> <PubMed>
3. Feigin VL, Mensah GA, Norrving B, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990–2013: The GBD 2013 Study Valery. Neuroepidemiology 2015; 45: 230–6. <https://doi.org/10.1159/000441106> <PubMed>
4. Nepal G, Ojha R, Dulal HP, Yadav BK. Association between Lys198Asn polymorphism of endothelin‐1 gene and ischemic stroke: A metaanalysis. Brain and Behavior 2019; 9(10): e01424. <https://doi.org/10.1002/brb3.1424> <PubMed>
5. Attia J, Thakkinstian A, Wang Y, et al. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 2007; 16: 173–9. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2007.03.002>
6. Nafría C, Fernández-Cadenas I, Mendioroz M, et al. Update on the serum biomarkers and genetic factors associated with safety and efficacy of rt-PA treatment in acute stroke patients. Stroke Research and Treatment 2011; 2011: 182783. <https://doi.org/10.4061/2011/182783> <PubMed>
7. Kamali M, Hantoushzadeh S, Borna S, et al. Association between thrombophilic genes polymorphisms and recurrent pregnancy loss susceptibility in the iranian population: A systematic review and meta-analysis. Iranian Biomedical Journal 2018; 22(2): 78–89.
8. Poole LG, Massey VL, Siow DL, et al. Plasminogen activator inhibitor- 1 is critical in alcohol-enhanced acute lung injury in mice. American Journal of Respiratory Cell and Molecular Biology 2017; 57: 315–23. <https://doi.org/10.1165/rcmb.2016-0184OC> <PubMed>
9. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. Journal of Thrombosis and Haemostasis: JTH 2007; 5(Suppl 1): 132–42. <https://doi.org/10.1111/j.1538-7836.2007.02464.x>
10. Gao W, Guo Y, Bai Y, Ding X, Yan Y, Wu Z. Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population. International Urology and Nephrology 2016; 48: 1483–9. <https://doi.org/10.1007/s11255-016-1333-9>
11. Bucan K, Plestina Borjan I, et al. Genetic Background of a Recurrent Unusual Combined Form of Retinal Vein Occlusion: A Case Report. Case Reports in Ophthalmology 2018; 9: 248–53. <https://doi.org/10.1159/000488234> <PubMed>
12. Sobhan MR, Mahdinezhad-Yazdi M, Moghimi M, et al. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis. The Archives of Bone and Joint Surgery 2018; 6: 468–77.
13. Ye Y, Vattai A, Zhang X, et al. Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases. International Journal of Molecular Sciences 2017; 18(8): 1651. <https://doi.org/10.3390/ijms18081651> <PubMed>
14. Chen C-H, Eng H-L, Chang C-J, et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. The Journal of Laboratory and Clinical Medicine 2003; 142: 100–5. <https://doi.org/10.1016/S0022-2143(03)00063-5>
15. Adamski MG, Turaj W, Slowik A, Wloch-Kopec D, Wolkow P, Szczudlik A. A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurologica Scandinavica 2009; 120: 94–100. <https://doi.org/10.1111/j.1600-0404.2008.01127.x>
16. Esparza-García JC, Santiago-Germán D, et al. GLU298ASP and 4G/5G Polymorphisms and the Risk of Ischemic Stroke in Young Individuals. The Canadian Journal of Neurological Sciences – Le Journal Canadien Des Sciences Neurologiques 2015; 42: 310–6. <https://doi.org/10.1017/cjn.2015.45>
17. Xu X, Li J, Sheng W, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovascular Diseases (Basel, Switzerland) 2008; 26: 48–62. <https://doi.org/10.1159/000135653>
18. Mousavi A, Karimi Zarchi M, Modares Gilani M, et al. Radical hysterectomy in the elderly. World Journal of Surgical Oncology 2008; 6: 38. <https://doi.org/10.1186/1477-7819-6-38> <PubMed>
19. Karimi Zarchi M, Akhavan A, Gholami H, Dehghani A, Naghshi M, Mohseni F. Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009. Asian Pacific Journal of Cancer Prevention: APJCP 2010; 11: 537–8.
20. Behtash N, Karimi Zarchi M, Deldar M. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran. Asian Pacific Journal of Cancer Prevention: APJCP 2009; 10: 613–8.
21. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovascular Diseases (Basel, Switzerland) 2001; 11: 294–9. <https://doi.org/10.1159/000047656>
22. Zhang C, Li J, Li L, Luo B. (The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease). Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics 2001; 18: 383–7.
23. Kain K, Young J, Bamford J, Bavington J, Grant PJ, Catto AJ. Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. Cerebrovascular Diseases (Basel, Switzerland) 2002; 14: 77–83. <https://doi.org/10.1159/000064732>
24. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. Journal of Cardiovascular Risk 2002; 9: 131–7. <https://doi.org/10.1097/00043798-200204000-00009>
25. Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. Journal of Thrombosis and Haemostasis: JTH 2003; 1: 1799–804. <https://doi.org/10.1046/j.1538-7836.2003.00255.x>
26. Yeh P-S, Lin H-J, Li Y-H, et al. Prognosis of young ischemic stroke in Taiwan: impact of prothrombotic genetic polymorphisms. Thrombosis and Haemostasis 2004; 92: 583–9. <https://doi.org/10.1160/TH04-03-0099>
27. Jood K, Ladenvall P, Tjärnlund-Wolf A, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005; 36: 2077–81. <https://doi.org/10.1161/01.STR.0000183617.54752.69>
28. Goor ML van, Gomez Garcia E, Leebeek F, et al. Blood Coagulation, Fibrinolysis and Cellular Haemostasis-The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thrombosis and Haemostasis 2005; 93: 92–6.
29. Wiklund PG, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor- 1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005; 36: 1661–5. <https://doi.org/10.1161/01.STR.0000174485.10277.24>
30. Komitopoulou A, Platokouki H, Kapsimali Z, Pergantou H, Adamtziki E, Aronis S. Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovascular Diseases (Basel, Switzerland) 2006; 22: 13–20. <https://doi.org/10.1159/000092332>
31. Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association n.d.; 16: 153–9. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2007.02.002>
32. De Paula Sabino A, Ribeiro DD, et al. Plasminogen activator inhibitor- 1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke. Molecular Biology Reports 2011; 38: 5355–60. <https://doi.org/10.1007/s11033-011-0687-4>
33. Balcerzyk A, Żak I, Emich-Widera E, et al. The plasminogen activator inhibitor-1 gene polymorphism in determining the risk of pediatric ischemic stroke--case control and family-based study. Neuropediatrics 2011; 42: 67–70.
34. Pruissen DMO, Rosendaal FR, Frijns CJM, Kappelle LJ, Vos HL, Algra A. Prothrombotic gene variants and mortality after cerebral ischemia of arterial origin. Neuroepidemiology 2011; 37: 109–13. <https://doi.org/10.1159/000330353>
35. Maguire J, Thakkinstian A, Levi C, et al. Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: A novel finding. Journal of Stroke and Cerebrovascular Diseases 2011; 20: 134–44. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.10.011>
36. Anunchai A, Narin, Sriratanaviriyakul Yupaporn L, Wanna TOP, Tongsima S, Manop P. Meta-analysis of the plasminogen activator inhibitor-1 (PAI-1) gene with insertion/deletion 4G/5G polymorphism and its susceptibility to ischemic stroke in Thai population. Asian Biomedicine 2012; 6(2): 203–17.
37. Babu MS, Prabha TS, Kaul S, et al. Association of genetic variants of fibrinolytic system with stroke and stroke subtypes. Gene 2012; 495: 76–80. <https://doi.org/10.1016/j.gene.2011.12.046>
38. Huang X, Li Y, Huang Z, Wang C, Xu Z. Pai-1 gene variants and COC use are associated with stroke risk: a case-control study in the Han Chinese women. Journal of Molecular Neuroscience: MN 2014; 54: 803–10. <https://doi.org/10.1007/s12031-014-0418-0>
39. Natesirinilkul R, Sasanakul W, Chuansumrit A, et al. Global fibrinolytic activity, PAI-1 level, and 4G/5G polymorphism in Thai children with arterial ischemic stroke. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 2014; 23: 2566–72. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.05.025>
40. Supanc V, Sonicki Z, Vukasovic I, Solter VV, Zavoreo I, Kes VB. The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals. Journal of Stroke and Cerebrovascular Diseases 2014; 23(3): e171–6. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.09.025>
41. Ranellou K, Paraskeva A, Kyriazopoulos P, et al. Polymorphisms in prothrombotic genes in young stroke patients in Greece: a case-controlled study. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis 2015; 26: 430–5. <https://doi.org/10.1097/MBC.0000000000000274>
42. Akhter N, Dar SA, Chattopadhyay S, et al. Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population. Current Genomics 2017; 19: 395–410. <https://doi.org/10.2174/1389202919666171205104137> <PubMed>
43. Coen Herak D, Lenicek Krleza J, Radic Antolic M, et al. Association of Polymorphisms in Coagulation Factor Genes and Enzymes of Homocysteine Metabolism With Arterial Ischemic Stroke in Children. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017; 23: 1042–51. <https://doi.org/10.1177/1076029616672584>
44. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thrombosis and Haemostasis 1997; 77: 730–4.
45. Cao Y, Chen W, Qian Y, Zeng Y, Liu W. Plasminogen activator inhibitor- 1 4G/5G polymorphism and ischemic stroke risk: a meta-analysis in Chinese population. The International Journal of Neuroscience 2014; 124: 874–81. <https://doi.org/10.3109/00207454.2014.886577>
46. Jeppesen LL, Wilhelmsen K, Nielsen LB, et al. An Insertion/Deletion polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene is associated with plasma levels but not with stroke risk in the elderly. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 1998; 7(6): 385–90. <https://doi.org/10.1016/S1052-3057(98)80121-3>
47. Endler G, Lalouschek W, Exner M, Mitterbauer G, Häring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. British Journal of Haematology 2000; 110: 469–71. <https://doi.org/10.1046/j.1365-2141.2000.02164.x>
48. Elbaz A, Cambien F, Amarenco P, GENIC investigators. Plasminogen activator inhibitor genotype and brain infarction. Circulation 2001; 103: e13–4; author reply e13–4. <https://doi.org/10.1161/01.CIR.103.2.e13>
49. Nowak-Göttl U, Sträter R, Kosch A, et al. The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group. European Journal of Haematology 2001; 66: 57–62. <https://doi.org/10.1034/j.1600-0609.2001.00338.x>
50. Hu X, Zan X, Xie Z, et al. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility. Molecular Neurobiology 2017; 54: 328–41. <https://doi.org/10.1007/s12035-015-9549-8>
51. Mirjalili SA, Moghimi M, Aghili K, et al. association of promoter region polymorphisms of interleukin-10 gene with susceptibility to colorectal cancer: a systematic review and meta-analysis. Arquivos de Gastroenterologia 2018; 55: 306–13. <https://doi.org/10.1590/s0004-2803.201800000-66>
52. Moghimi M, Kargar S, Jafari MA, et al. Angiotensin Converting Enzyme Insertion/Deletion Polymorphism is Associated with Breast Cancer Risk: A Meta-Analysis. Asian Pac J Cancer Prev 2018; 19: 3225–31. <https://doi.org/10.31557/APJCP.2018.19.11.3225> <PubMed>
53. Moghimi M, Sobhan MR, Jarahzadeh MH, et al. Association of GSTM1, GSTT1, GSTM3, and GSTP1 Genes Polymorphisms with Susceptibility to Osteosarcoma: a Case- Control Study and Meta-Analysis. Asian Pac J Cancer Prev 2019; 20: 675–82. <https://doi.org/10.31557/APJCP.2019.20.3.675> <PubMed>
54. Jafari-Nedooshan J, Moghimi M, Zare M, et al. Association of Promoter Region Polymorphisms of IL-10 Gene with Susceptibility to Lung Cancer: Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2019; 20: 1951–7. <https://doi.org/10.31557/APJCP.2019.20.7.1951> <PubMed>
55. Farbod M, Karimi-Zarchi M, Heiranizadeh N, et al. Association of TNF-α -308G>A Polymorphism with Susceptibility to Cervical Cancer and Breast Cancer – a Systematic Review and Meta-analysis. Klinicka Onkologie 2019; 32: 170–80. <https://doi.org/10.14735/amko2019170>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Archive